Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
  • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
  • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
  • Y02P20/00—Technologies relating to chemical industry
  • Y02P20/50—Improvements relating to the production of bulk chemicals
  • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

• the present invention relates to a method of obtaining an intermediate, useful for the production of (+/ ⁇ )-5-[[4-[2-(5-ethyl-2-pyridyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione (termed pioglitazone hereinafter) of formula I
• Pioglitazone belongs to the thiazolidinedione group of antidiabetics. This compound and its antidiabetic properties were described in EP 193 256. Later it was found that its antidiabetic effect consists in reducing insulin resistance, thereby improving glucose availability without increasing insulin secretion, unlike most other antidiabetics. For these extraordinary characteristics this product is of great importance for the treatment of non-insulin dependent diabetes mellitus. Combining with insulin or other antidiabetics can further increase its effect.
• the reactions are carried out in alkaline environment in organic solvents (e.g., dimethylformamide).
• organic solvents e.g., dimethylformamide
• EP 193 256 discloses another reaction, which can be described by the following scheme
• a major drawback of this method is non-standard course of the reduction of the nitro group on palladium (reaction time is 3 hours up to several days), which is apparently dependent on the contents of impurities in the starting compound and in the solvent.
• the impurities apparently cause poisoning of the catalyst; therefore additional catalyst has to be gradually added. Longer reaction time results in formation of larger amounts of impurities and lower yields.
• the product of formula X further reacts with thiazolidinedione yielding a benzylidene compound of formula XI which is converted to pioglitazone (formula I) by reducing on palladium.
• a drawback of the above-described methods is necessity of pressure reduction of the double bond of compound XI, i.e. 5-(4-(2-(5-ethyl-2-pyridyl)ethoxy)benzylidene)-2,4-thiazolidinedione.
• the following methods are known:
• the solution in accordance with the present invention involves condensing 4-derivatized phenol or phenolate with a pyridine base of general formula III
• Z is a leaving group other than a halogen, the starting compound of formula II wherein R is an amino group-containing organic residue, selected from the group comprising a residue of general formula —NHR a wherein R a is hydrogen or a protecting group, which is removed before further treatment,
• R b represents a carboxy group either in the free acid form or in the form of a salt or ester of another functional derivative of the nitrile group CN, and M represents a hydrogen atom or an alkali metal, being subjected, before or after carrying out the condensation, to the following operations:
• Diazotizing is preformed from the bromohydride of the respective aniline derivative or amino acid by drop-by-drop adding a solution of sodium nitrite in water at about 5° C.
• Cyclizing with thiourea is carried out in ethanol at its boiling point with subsequent separation of the product.
• the condensation with 2-(5-ethyl-2-pyridyl)ethyl derivative itself is carried out in the presence of a base in the form of an alkali metal carbonate, hydroxide or hydride in an organic solvent or in a heterogeneous mixture of an organic solvent and water.
• a base in the form of an alkali metal carbonate, hydroxide or hydride in an organic solvent or in a heterogeneous mixture of an organic solvent and water.
• the temperature when performed in an organic solvent ranges between 50 and 130° C.
• the solvent can be evaporated, or, if it is a high-boiling solvent, water is added to the mixture.
• the product is extracted with ethyl acetate.
• R is a residue of formula —NHR a wherein R a is as defined above, then condensing of compounds II and III results in a compound of formula V Where R a is a leaving group, then formula V represents a yet undisclosed compound.
• the selection of the leaving group R a is not essential for further procedure. It can be selected among the groups such as acyl, n-alkyloxycarbonyl, tert-butyloxycarbonyl, benzyloxycarbonyl, 9-fluorenylmethyloxycarbonyl, allyloxycarbonyl, 2-cyanoethoxycarbonyl, dimethylaminomethylenyl or hexa-2,4-dien-2,5-diyl.
• R a can be an acyl group derived from lower aliphatic acids (C 1 to C 4 ), such as acetyl, or from lower aromatic acids, such as benzoyl.
• Degradation of the compound of formula V results in a compound of formula IV wherein m stands for 0 (for a free amine) or 1 (for ammonium salt), R 0 is a mineral or organic acid residue such as a halogen, HSO 4 ⁇ , NO 3 ⁇ , R 1 COO— or R 1 SO 3 —, wherein R 1 represents hydrogen or a hydrocarbon residue, which can be advantageously used for the preparation of pioglitazone.
• the hydrolysis itself is carried out with a mineral or organic acid of general formula HR 0 or with a base.
• compound IV represents 4-(2-(5-ethyl-2-pyridyl)ethoxy)aniline, i.e. the free base (m is 0).
• haloacids such as hydrochloric acid
• hydrobromic acid is especially preferable for hydrolysis of compound of formula V, when R 0 represents Br and the product of formula IV, 4-(2-(5-ethyl-2-pyridyl)ethoxy)aniline hydrobromide, need not to be isolated.
• Oxygen-containing mineral acids such as sulphuric acid can also be used in the hydrolysis.
• Useful organic acids include alkyl- or arylsulfonic acids (such as methanesulfonic acid). Numerous carboxylic acids such as formic or acetic acids can be used for the hydrolysis.
• the compound of formula IV is further treated in a known manner, i.e. by diazotizing, Meerwein reaction, cyclizing with thiourea and hydrolysing the imine. This method has been described in EP 193 256 and is here depicted in Scheme 1.
• R is a residue of formula wherein R b is carboxyl or nitrile
• an intermediate of formula VI is formed, with which the condensation is subsequently carried out.
• the starting compound can be the amino acid tyrosine
• an inexpensive natural source of formula Condensation of intermediate VI with base III can in this case be made in an organic polar solvent such as dimethylformamide or dimethylsulfoxide.
• the reaction temperature is selected in dependence of the base employed in the range of from 70 to 130° C.
• the reaction time ranges, again in connection with the selected base, between 0.5 and 3 hours.
• the reaction mixture is quenched with water and the product is extracted, usually with acetate.
• R is a protected amine of formula —NHR a
• the most preferable composition is the case when R a is acetyl, and the compound of formula II is widely used paracetamol.
• the condensation in this case is preferably carried out in ethanol at 50° C. After the reaction is complete ethanol is evaporated and the product extracted with ethyl acetate.
• Tyrosine (20 g) is dissolved in HBr (100 ml, 48% diluted with 200 ml water). To the cooled solution NaNO 2 in 30 ml water is added dropwise. The product is extracted with ethyl acetate and after common treatment 2-bromo-3-(4-hydroxyphenyl)-propionic acid is obtained, which is used without purification for the next step.
• the product can be recrystallized from a mixture ethyl acetate-heptane. 9.5 g of 5-(4-hydroxybenzyl)-1,3-thiazolidine-2,4-dione having a melting point 150.9–152.5° C. is obtained.
• the semi-solid residue is mixed in water and the solid portion of 5-[[4-[2-(5-ethyl-2-pyridyl) ethoxy]phenyl]methyl]-2.4-thiazolidinedione (0.18 g) is filtered off and recrystallized from the mixture DMF-water.
• acrylonitrile (16.8 ml) is added and the temperature is elevated to 38° C. Cuprous oxide (0.5 g) is added in small portions. The mixture is agitated until release of nitrogen stops, then concentrated under reduced pressure, the concentrate is alkalified by adding an aqueous ammonia solution and extracted with ethyl acetate. The ethylacetate layer is washed with water and dried over sodium sulfate. Evaporating the solvent gives the nitrile of 2-bromo-3-[4-(2-(5-ethyl-2-pyridyl)ethoxy)phenyl]-propionic acid as crude oil (18.7 g, 99% of theory).

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Diabetes (AREA)
• Medicinal Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Hematology (AREA)
• Obesity (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Emergency Medicine (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pharmacology & Pharmacy (AREA)
• Endocrinology (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Saccharide Compounds (AREA)
• Pyridine Compounds (AREA)

Applications Claiming Priority (5)

Publications (2)

Family

ID=25746959

Family Applications (1)

Country Status (11)

Cited By (1)

Families Citing this family (17)

Citations (5)

Family Cites Families (1)

• 2002
  • 2002-04-25 US US10/475,099 patent/US7009057B2/en not_active Expired - Fee Related
  • 2002-04-25 PL PL02363738A patent/PL363738A1/xx not_active Application Discontinuation
  • 2002-04-25 EP EP02734989A patent/EP1387843B1/de not_active Expired - Lifetime
  • 2002-04-25 AU AU2002311057A patent/AU2002311057A1/en not_active Abandoned
  • 2002-04-25 HU HU0400091A patent/HUP0400091A2/hu unknown
  • 2002-04-25 RU RU2003134542/04A patent/RU2281285C2/ru not_active IP Right Cessation
  • 2002-04-25 WO PCT/CZ2002/000024 patent/WO2002088120A1/en not_active Ceased
  • 2002-04-25 EE EEP200300519A patent/EE200300519A/xx unknown
  • 2002-04-25 DE DE60218449T patent/DE60218449D1/de not_active Expired - Lifetime
  • 2002-04-25 AT AT02734989T patent/ATE355286T1/de not_active IP Right Cessation
  • 2002-04-25 SK SK1445-2003A patent/SK14452003A3/sk unknown

Patent Citations (5)

Also Published As

Similar Documents

Legal Events